28 related articles for article (PubMed ID: 9676756)
1. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors.
Campagne O; Huang J; Lin T; Reddick WE; Selvo NS; Onar-Thomas A; Ward D; Robinson G; Gajjar A; Stewart CF
Eur J Pharm Sci; 2024 Feb; 193():106669. PubMed ID: 38070781
[TBL] [Abstract][Full Text] [Related]
2. External Evaluation of Population Pharmacokinetic Models for High-Dose Methotrexate in Adult Patients with Hematological Tumors.
Chen S; Huang L; Huang W; Zheng Y; Shen L; Liu M; Chen W; Wu X
J Clin Pharmacol; 2024 Apr; 64(4):437-448. PubMed ID: 38081138
[TBL] [Abstract][Full Text] [Related]
3. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients.
Bressolle F; Bologna C; Kinowski JM; Arcos B; Sany J; Combe B
J Rheumatol; 1997 Oct; 24(10):1903-9. PubMed ID: 9330930
[TBL] [Abstract][Full Text] [Related]
4. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
5. Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis?
Carpentier N; Bertin P; Marquet P; Sabot C; Bonnet C; Debord J; Lachâtre G; Trèves R
J Rheumatol; 1998 Jul; 25(7):1270-5. PubMed ID: 9676755
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
[TBL] [Abstract][Full Text] [Related]
7. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
[TBL] [Abstract][Full Text] [Related]
8. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.
Monjanel-Mouterde S; Lafforgue P; Blanc A; Catalin J; Aquaviva PC; Durand A
J Rheumatol; 1998 Jul; 25(7):1276-81. PubMed ID: 9676756
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications].
Bannwarth B; Péhourcq F; Lequen L
Therapie; 1997; 52(2):129-32. PubMed ID: 9231507
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
[TBL] [Abstract][Full Text] [Related]
11. [Bayesian estimation of pharmacokinetic parameters of etoposide].
Evene E; Chatelut E; Tranchand B; Canal P; Lochon I; Iliadis A; Ardiet CJ
Bull Cancer; 1997 Jul; 84(7):699-703. PubMed ID: 9339195
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics.
Methaneethorn J; AlEjielat R; Leelakanok N
Drug Metab Pers Ther; 2022 Sep; 37(3):229-240. PubMed ID: 35218177
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]